he AMDA was saddened to learn of the sudden passing of Henri Termeer, former CEO of Genzyme.
We have known and worked with Henri since the late-90s through his role as the CEO of Genzyme. We will never forget how he always took the time to talk to patients and their families—to learn from them.
The IPA said it best in their tribute to Henri: “In the Pompe Community we have a true partnership between the three stakeholders: the Medical/Scientific Community, Industry, and the Patient Community. This partnership is only possible when all parties respect and value each other. The IPA believes that Henri Termeer was instrumental in setting the tone for Industry partners to engage with, and learn from their counter-parts in the Patient Community. He will be greatly missed.”
On behalf of the AMDA-thank you Henri. Thank you for all you did to embrace and include the patients’ experiences and perspectives throughout the drug development process. You will be missed.